These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37950424)

  • 1. Efficacy and toxicity of drugs targeting KRAS
    Luo W; Zhu J; Zhang W; Yu A; Zhou W; Xu K
    Expert Rev Anticancer Ther; 2023; 23(12):1295-1303. PubMed ID: 37950424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Garsorasib in patients with KRAS
    Li Z; Dang X; Huang D; Jin S; Li W; Shi J; Wang X; Zhang Y; Song Z; Zhang J; Zhuang W; Liu X; Jiang L; Meng X; Zhao M; Zhou J; Zhang L; Wang P; Luo H; Yang J; Cang S; Wang X; Zhang L; Lu S;
    Lancet Respir Med; 2024 Aug; 12(8):589-598. PubMed ID: 38870979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
    Mausey N; Halford Z
    Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study.
    Chen M; Huang Y; Jiang S; Ke C
    Lung Cancer; 2024 Oct; 196():107966. PubMed ID: 39342769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adagrasib: a novel inhibitor for
    Guo MZ; Marrone KA; Spira A; Rosner S
    Future Oncol; 2023 May; 19(15):1037-1051. PubMed ID: 37133216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced
    Ou SI; Jänne PA; Leal TA; Rybkin II; Sabari JK; Barve MA; Bazhenova L; Johnson ML; Velastegui KL; Cilliers C; Christensen JG; Yan X; Chao RC; Papadopoulos KP
    J Clin Oncol; 2022 Aug; 40(23):2530-2538. PubMed ID: 35167329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.
    Hochmair MJ; Vermaelen K; Mountzios G; Carcereny E; Dooms C; Lee SH; Morocz E; Kato T; Ciuleanu TE; Dy GK; Parente B; O'Byrne KJ; Chu QS; Castro Junior G; Girard N; Snyder W; Tran Q; Kormany W; Houk B; Mehta B; Curioni-Fontecedro A
    Eur J Cancer; 2024 Sep; 208():114204. PubMed ID: 39029295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes following KRAS
    Chen QA; Lin WH; Zhou XX; Cao Z; Feng XL; Gao YB; He J
    Pharmacol Res; 2024 Feb; 200():107060. PubMed ID: 38185210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adagrasib in Non-Small-Cell Lung Cancer Harboring a
    Jänne PA; Riely GJ; Gadgeel SM; Heist RS; Ou SI; Pacheco JM; Johnson ML; Sabari JK; Leventakos K; Yau E; Bazhenova L; Negrao MV; Pennell NA; Zhang J; Anderes K; Der-Torossian H; Kheoh T; Velastegui K; Yan X; Christensen JG; Chao RC; Spira AI
    N Engl J Med; 2022 Jul; 387(2):120-131. PubMed ID: 35658005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and toxicity of KRAS
    Dang S; Zhang S; Zhao J; Li W
    World J Surg Oncol; 2024 Jul; 22(1):182. PubMed ID: 39010022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
    Nakajima EC; Drezner N; Li X; Mishra-Kalyani PS; Liu Y; Zhao H; Bi Y; Liu J; Rahman A; Wearne E; Ojofeitimi I; Hotaki LT; Spillman D; Pazdur R; Beaver JA; Singh H
    Clin Cancer Res; 2022 Apr; 28(8):1482-1486. PubMed ID: 34903582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
    Lee A
    Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With
    Luo J; Florez N; Donnelly A; Lou Y; Lu K; Ma PC; Spira AI; Ryan D; Husain H
    JCO Precis Oncol; 2024 Apr; 8():e2300644. PubMed ID: 38579193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS
    Li Z; Song Z; Zhao Y; Wang P; Jiang L; Gong Y; Zhou J; Jian H; Dong X; Zhuang W; Cang S; Yang N; Fang J; Shi J; Lu J; Ma R; Wu P; Zhang Y; Song M; Xu CW; Shi Z; Zhang L; Wang Y; Wang X; Zhang Y; Lu S
    J Thorac Oncol; 2023 Jul; 18(7):940-951. PubMed ID: 36948246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy.
    Justeau G; Huchot E; Simonneau Y; Roa M; Le Treut J; Le Garff G; Bylicki O; Schott R; Bravard AS; Tiercin M; Lamy R; De Chabot G; Marty A; Moreau D; Locher C; Bernier C; Chouaid C; Descourt R
    Lung Cancer; 2022 Dec; 174():45-49. PubMed ID: 36323057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
    Blumenschein GR; Smit EF; Planchard D; Kim DW; Cadranel J; De Pas T; Dunphy F; Udud K; Ahn MJ; Hanna NH; Kim JH; Mazieres J; Kim SW; Baas P; Rappold E; Redhu S; Puski A; Wu FS; Jänne PA
    Ann Oncol; 2015 May; 26(5):894-901. PubMed ID: 25722381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS
    Hoshiyama H
    Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With
    Negrao MV; Spira AI; Heist RS; Jänne PA; Pacheco JM; Weiss J; Gadgeel SM; Velastegui K; Yang W; Der-Torossian H; Christensen JG; Sabari JK
    J Clin Oncol; 2023 Oct; 41(28):4472-4477. PubMed ID: 37327468
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.